Quality of Life in Allergic Rhinoconjunctivitis Patients Treated With Dialyzable Leukocyte Extracts

Phase 2 Completed 30 enrolled National Polytechnic Institute, Mexico Instituto de Oftalmología Fundación Conde de Valenciana · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the changes of quality of life of patients with allergic rhinoconjunctivitis treated with standard medications plus Dialyzable Leukocyte Extracts (DLE). All patients will receive DLE in combination with current guide lines-suggested standard medication.

Timeline

Start: 2013-08
Primary completion: 2015-01
Completion: 2015-01

Outcome

Met primary endpoint

paper After 11 weeks, the mean RQLQ score was 1.74 ± 1.09 ( P < .0001; 95% confidence interval [CI], 1.05-2.33) PMID 37417619 ↗

paper Each of the 28 individual item scores on the RQLQ showed clinical (minimal important difference [MID] ≥ 0.5) and statistical ( P < .05) improvements. PMID 37417619 ↗

Publications

Homberg TA, Lara I, Andaluz C, Cervantes-Trujano E, Hernandez-Martinez PM, Perez-Tapia SM, Jimenez-Martinez MC. Quality of life in adult patients using dialyzable leukocyte extract for allergic rhinitis. Medicine (Baltimore). 2023 Jul 7;102(27):e34186. doi: 10.1097/MD.0000000000034186.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DLE	Peptide	2 mg	Oral